922727-37-5

922727-37-5 structure

Name: Pantoprazole-d3
Chemical Name: 1H-Benzimidazole, 6-(difluoromethoxy)-2-[[[3-methoxy-4-(methoxy-d3)-2-pyridinyl]methyl]sulfinyl]
CAS Number: 922727-37-5
Molecular Formula: C₁₆H₁₂D₃F₂N₃O₄S
Molecular Weight: 386.39
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2016-01-15 23:26:53
Modify Date: 2024-01-08 17:20:09
Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

Name	1H-Benzimidazole, 6-(difluoromethoxy)-2-[[[3-methoxy-4-(methoxy-d3)-2-pyridinyl]methyl]sulfinyl]
Synonyms	Pantoprazole-d3

Description	Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Inflammation/Immunology Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19(24):6766-76. [3]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [4]. W Beil, et al. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71. [5]. K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.

Molecular Formula	C₁₆H₁₂D₃F₂N₃O₄S
Molecular Weight	386.39
Exact Mass	383.07500
PSA	105.54000
LogP	3.75000

922727-37-5	1190008-84-4
138786-67-1	102625-64-9
2115779-15-0	102625-70-7
1022083-88-0	164579-32-2
142706-18-1	1279822-90-0